Antibody Drug Conjugates Market Set for Major Growth: 2025-2033 Outlook

Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Urothelial Carcinoma, Ovarian Cancer, Breast Cancer, Other Cancer), Product, Payload, Technology, Distribution Channel and Region with Growth Forecasts, 2025-2033" has been added to ResearchAndMarkets.com's offering. The global antibody-drug conjugates (ADCs) market is on a robust growth trajectory, with a projected market size of USD 32.11 billion by 2033, from USD 12.26 billion in 2024. This translates to a compound annual growth rate (CAGR) of 10.49% from 2025 to 2033. This dynamic expansion is driven chiefly by the increasing prevalence of cancer and the escalating demand for targeted therapies that maximize efficacy and minimize systemic toxicity. Recent advancements in targeted therapies, coupled with a surge in clinical trials and strategic investments from pharmaceutical giants, are propelling the ADC market forward. Ongoing research and development, particularly in targeted therapy and precision medicine, have bolstered the appeal of ADCs, positioning them as a preferred oncology treatment option. The global rise in cancer incidence necessitates the development of therapies known for high efficacy and reduced adverse effects. ADCs meet these needs by targeting cancer cells directly, minimizing damage to healthy cells, thus enhancing patient outcomes. The increasing number of clinical trials and regulatory endorsements signify significant commitment levels from pharmaceutical companies to innovate in this arena. Industry milestones include the approval of Datroway (datopotamab deruxtecan) in June 2025 by the U.S., earmarking it for advanced non-small cell lung cancer in pre-treated adults. Similarly, in February 2025, the FDA greenlit Datroway for certain breast cancer treatments. Additionally, GSK's Blenrep received regulatory approval in the UK for treating multiple myeloma in April 2025. These approvals underscore the growing validation and reliance on ADC therapies in the healthcare sector. Global Antibody Drug Conjugates Market Report Segmentation This report offers a comprehensive revenue growth forecast at global, regional, and country levels, analyzing the latest trends across sub-segments from 2021 to 2033. It segments the global ADC market by application, product, payload, technology, distribution channel, and region: Application Outlook (Revenue, USD Million, 2021-2033) Breast Cancer Blood Cancer Urothelial Carcinoma Ovarian Cancer Others Product Outlook (Revenue, USD Million, 2021-2033) Kadcyla (ado-trastuzumab emtansine) Enhertu (trastuzumab deruxtecan) Trodelvy (sacituzumab govitecan) Adcetris (brentuximab vedotin) Polivy (polatuzumab vedotin) Others (Padcev, Tivdak, Elahere, Zynlonta, Mylotarg, Besponsa) Payload Outlook (Revenue, USD Million, 2021-2033) Auristatins (MMAE, MMAF) Maytansinoids (DM1, DM4) Calicheamicin Derivatives Topoisomerase I Inhibitors (SN-38, DXd) Pyrrolobenzodiazepine (PBD) Dimers Others Technology Outlook (Revenue, USD Million, 2021-2033) Cleavable Linker Non-Cleavable Linker Others Distribution Channel Outlook (Revenue, USD Million, 2021-2033) Hospital Pharmacy Specialty Pharmacy Others Regional Outlook (Revenue, USD Million, 2021-2033) North America Europe Asia Pacific Latin America Middle East & Africa Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover pivotal trends and drivers shaping the market's future. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. This report addresses: Market intelligence for effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Revenue forecasts for market assessment by segment and region Competition strategy and market share analysis Product innovation listings to stay ahead of the curve Key Attributes: Report AttributeDetailsNo. of Pages150Forecast Period2024 - 2033Estimated Market Value (USD) in 2024$12.26 BillionForecasted Market Value (USD) by 2033$32.11 BillionCompound Annual Growth Rate10.4%Regions CoveredGlobal Companies Featured The key companies profiled in this Antibody Drug Conjugates market report include: Seagen, Inc. Takeda Pharmaceutical Company Ltd. AstraZeneca F. Hoffmann-La Roche Ltd. Pfizer, Inc. Gilead Sciences, Inc. Daiichi Sankyo Company Ltd. Antibody Drug Conjugates Therapeutics SA For more information about this report visit https://www.researchandmarkets.com/r/yzowel About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Drug Conjugates Market